Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial
Identifieur interne : 000900 ( Istex/Corpus ); précédent : 000899; suivant : 000901Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial
Auteurs : Erich Mohr ; Tilak Mendis ; Kathleen Hildebrand ; Peter Paul De DeynSource :
- Movement Disorders [ 0885-3185 ] ; 2000-11.
English descriptors
Abstract
PURPOSE: To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine‐induced psychosis. PATIENTS AND METHODS: Seventeen patients (median age, 72 yrs) participated in this 12‐week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued. EFFICACY RESULTS: Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (−3.1 decrease) after 1 week and a 66% improvement (−6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)‐severity and CGI‐improvement (p <0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). SAFETY RESULTS: Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs. CONCLUSION: Short‐term use of risperidone (mean dosage, 1.1 mg per day) improves the psychopathology of patients with PD who have dopamine‐induced psychosis without adversely affecting the symptoms of PD. Higher doses and long‐term use were not addressed in this study and may be precluded by extrapyramidal side effects.
Url:
DOI: 10.1002/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9
Links to Exploration step
ISTEX:8B1FBAD976A77EB092B13F06364277175FC64B7ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial</title><author><name sortKey="Mohr, Erich" sort="Mohr, Erich" uniqKey="Mohr E" first="Erich" last="Mohr">Erich Mohr</name><affiliation><mods:affiliation>CroMedica Global Inc., Victoria, Canada and University of Ottawa, Canada</mods:affiliation></affiliation></author><author><name sortKey="Mendis, Tilak" sort="Mendis, Tilak" uniqKey="Mendis T" first="Tilak" last="Mendis">Tilak Mendis</name><affiliation><mods:affiliation>Ottawa Civic Hospital and University of Ottawa, Canada</mods:affiliation></affiliation></author><author><name sortKey="Hildebrand, Kathleen" sort="Hildebrand, Kathleen" uniqKey="Hildebrand K" first="Kathleen" last="Hildebrand">Kathleen Hildebrand</name><affiliation><mods:affiliation>CroMedica Global Inc., Victoria, Canada and University of Ottawa, Canada</mods:affiliation></affiliation></author><author><name sortKey="De Deyn, Peter Paul" sort="De Deyn, Peter Paul" uniqKey="De Deyn P" first="Peter Paul" last="De Deyn">Peter Paul De Deyn</name><affiliation><mods:affiliation>Middelheim Hospital, University of Antwerp, Antwerp, Belgium</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8B1FBAD976A77EB092B13F06364277175FC64B7A</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1002/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9</idno><idno type="url">https://api.istex.fr/document/8B1FBAD976A77EB092B13F06364277175FC64B7A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000900</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial</title><author><name sortKey="Mohr, Erich" sort="Mohr, Erich" uniqKey="Mohr E" first="Erich" last="Mohr">Erich Mohr</name><affiliation><mods:affiliation>CroMedica Global Inc., Victoria, Canada and University of Ottawa, Canada</mods:affiliation></affiliation></author><author><name sortKey="Mendis, Tilak" sort="Mendis, Tilak" uniqKey="Mendis T" first="Tilak" last="Mendis">Tilak Mendis</name><affiliation><mods:affiliation>Ottawa Civic Hospital and University of Ottawa, Canada</mods:affiliation></affiliation></author><author><name sortKey="Hildebrand, Kathleen" sort="Hildebrand, Kathleen" uniqKey="Hildebrand K" first="Kathleen" last="Hildebrand">Kathleen Hildebrand</name><affiliation><mods:affiliation>CroMedica Global Inc., Victoria, Canada and University of Ottawa, Canada</mods:affiliation></affiliation></author><author><name sortKey="De Deyn, Peter Paul" sort="De Deyn, Peter Paul" uniqKey="De Deyn P" first="Peter Paul" last="De Deyn">Peter Paul De Deyn</name><affiliation><mods:affiliation>Middelheim Hospital, University of Antwerp, Antwerp, Belgium</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-11">2000-11</date><biblScope unit="vol">15</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1230">1230</biblScope><biblScope unit="page" to="1237">1237</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8B1FBAD976A77EB092B13F06364277175FC64B7A</idno><idno type="DOI">10.1002/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9</idno><idno type="ArticleID">MDS1026</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Extrapyramidal symptoms</term><term>Parkinson's disease</term><term>Psychosis</term><term>Risperidone</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">PURPOSE: To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine‐induced psychosis. PATIENTS AND METHODS: Seventeen patients (median age, 72 yrs) participated in this 12‐week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued. EFFICACY RESULTS: Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (−3.1 decrease) after 1 week and a 66% improvement (−6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)‐severity and CGI‐improvement (p <0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). SAFETY RESULTS: Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs. CONCLUSION: Short‐term use of risperidone (mean dosage, 1.1 mg per day) improves the psychopathology of patients with PD who have dopamine‐induced psychosis without adversely affecting the symptoms of PD. Higher doses and long‐term use were not addressed in this study and may be precluded by extrapyramidal side effects.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Erich Mohr PhD</name><affiliations><json:string>CroMedica Global Inc., Victoria, Canada and University of Ottawa, Canada</json:string></affiliations></json:item><json:item><name>Tilak Mendis MD, FRCP(C)</name><affiliations><json:string>Ottawa Civic Hospital and University of Ottawa, Canada</json:string></affiliations></json:item><json:item><name>Kathleen Hildebrand</name><affiliations><json:string>CroMedica Global Inc., Victoria, Canada and University of Ottawa, Canada</json:string></affiliations></json:item><json:item><name>Peter Paul De Deyn MD</name><affiliations><json:string>Middelheim Hospital, University of Antwerp, Antwerp, Belgium</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Risperidone</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Psychosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Extrapyramidal symptoms</value></json:item></subject><language><json:string>eng</json:string></language><abstract>PURPOSE: To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine‐induced psychosis. PATIENTS AND METHODS: Seventeen patients (median age, 72 yrs) participated in this 12‐week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued. EFFICACY RESULTS: Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (−3.1 decrease) after 1 week and a 66% improvement (−6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)‐severity and CGI‐improvement (p >0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). SAFETY RESULTS: Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs. CONCLUSION: Short‐term use of risperidone (mean dosage, 1.1 mg per day) improves the psychopathology of patients with PD who have dopamine‐induced psychosis without adversely affecting the symptoms of PD. Higher doses and long‐term use were not addressed in this study and may be precluded by extrapyramidal side effects.</abstract><qualityIndicators><score>7.131</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1719</abstractCharCount><pdfWordCount>4287</pdfWordCount><pdfCharCount>28557</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>237</abstractWordCount></qualityIndicators><title>Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial</title><genre><json:string>Serial article</json:string></genre><host><volume>15</volume><pages><total>8</total><last>1237</last><first>1230</first></pages><issn><json:string>0885-3185</json:string></issn><issue>6</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2000</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1002/1531-8257(200011)15:6>1230::AID-MDS1026>3.0.CO;2-9</json:string></doi><id>8B1FBAD976A77EB092B13F06364277175FC64B7A</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/8B1FBAD976A77EB092B13F06364277175FC64B7A/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/8B1FBAD976A77EB092B13F06364277175FC64B7A/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/8B1FBAD976A77EB092B13F06364277175FC64B7A/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>John Wiley & Sons, Inc.</p></availability><date>2000</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial</title><author><persName><forename type="first">Erich</forename><surname>Mohr</surname><roleName type="degree">PhD</roleName></persName><note type="correspondence"><p>Correspondence: CroMedica Global Inc., 600‐730 View Street, Victoria BC, V8W 3Y7, Canada</p></note><affiliation>CroMedica Global Inc., Victoria, Canada and University of Ottawa, Canada</affiliation></author><author><persName><forename type="first">Tilak</forename><surname>Mendis</surname><roleName type="degree">MD, FRCP(C)</roleName></persName><affiliation>Ottawa Civic Hospital and University of Ottawa, Canada</affiliation></author><author><persName><forename type="first">Kathleen</forename><surname>Hildebrand</surname></persName><affiliation>CroMedica Global Inc., Victoria, Canada and University of Ottawa, Canada</affiliation></author><author><persName><forename type="first">Peter Paul</forename><surname>De Deyn</surname><roleName type="degree">MD</roleName></persName><affiliation>Middelheim Hospital, University of Antwerp, Antwerp, Belgium</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-11"></date><biblScope unit="vol">15</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1230">1230</biblScope><biblScope unit="page" to="1237">1237</biblScope></imprint></monogr><idno type="istex">8B1FBAD976A77EB092B13F06364277175FC64B7A</idno><idno type="DOI">10.1002/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9</idno><idno type="ArticleID">MDS1026</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>PURPOSE: To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine‐induced psychosis. PATIENTS AND METHODS: Seventeen patients (median age, 72 yrs) participated in this 12‐week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued. EFFICACY RESULTS: Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (−3.1 decrease) after 1 week and a 66% improvement (−6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)‐severity and CGI‐improvement (p <0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). SAFETY RESULTS: Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs. CONCLUSION: Short‐term use of risperidone (mean dosage, 1.1 mg per day) improves the psychopathology of patients with PD who have dopamine‐induced psychosis without adversely affecting the symptoms of PD. Higher doses and long‐term use were not addressed in this study and may be precluded by extrapyramidal side effects.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Risperidone</term></item><item><term>Parkinson's disease</term></item><item><term>Psychosis</term></item><item><term>Extrapyramidal symptoms</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1999-09-28">Received</change><change when="2000-05-09">Registration</change><change when="2000-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/8B1FBAD976A77EB092B13F06364277175FC64B7A/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/1531-8257(200011)15:6<>1.0.CO;2-D</doi><numberingGroup><numbering type="journalVolume" number="15">15</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2000-11">November 2000</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="26" status="forIssue"><doi origin="wiley" registered="yes">10.1002/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9</doi><idGroup><id type="unit" value="MDS1026"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2000 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="1999-09-28"></event><event type="manuscriptRevised" date="2000-05-09"></event><event type="manuscriptAccepted" date="2000-05-09"></event><event type="firstOnline" date="2001-01-17"></event><event type="publishedOnlineFinalForm" date="2001-01-17"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-04"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1230</numbering><numbering type="pageLast">1237</numbering></numberingGroup><correspondenceTo>CroMedica Global Inc., 600‐730 View Street, Victoria BC, V8W 3Y7, Canada</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1026.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="50"></count><count type="wordTotal" number="4166"></count></countGroup><titleGroup><title type="main" xml:lang="en">Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial</title><title type="short" xml:lang="en">Risperidone in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Erich</givenNames><familyName>Mohr</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Tilak</givenNames><familyName>Mendis</familyName><degrees>MD, FRCP(C)</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Kathleen</givenNames><familyName>Hildebrand</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Peter Paul</givenNames><familyName>De Deyn</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="CA" type="organization"><unparsedAffiliation>CroMedica Global Inc., Victoria, Canada and University of Ottawa, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="CA" type="organization"><unparsedAffiliation>Ottawa Civic Hospital and University of Ottawa, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="BE" type="organization"><unparsedAffiliation>Middelheim Hospital, University of Antwerp, Antwerp, Belgium</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Risperidone</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">Psychosis</keyword><keyword xml:id="kwd4">Extrapyramidal symptoms</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">PURPOSE</title><p>To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine‐induced psychosis.</p></section><section xml:id="abs1-2"><title type="main">PATIENTS AND METHODS</title><p>Seventeen patients (median age, 72 yrs) participated in this 12‐week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued.</p></section><section xml:id="abs1-3"><title type="main">EFFICACY RESULTS</title><p>Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (−3.1 decrease) after 1 week and a 66% improvement (−6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)‐severity and CGI‐improvement (p <0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS).</p></section><section xml:id="abs1-4"><title type="main">SAFETY RESULTS</title><p>Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs.</p></section><section xml:id="abs1-5"><title type="main">CONCLUSION</title><p>Short‐term use of risperidone (mean dosage, 1.1 mg per day) improves the psychopathology of patients with PD who have dopamine‐induced psychosis without adversely affecting the symptoms of PD. Higher doses and long‐term use were not addressed in this study and may be precluded by extrapyramidal side effects.</p></section></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Risperidone in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial</title></titleInfo><name type="personal"><namePart type="given">Erich</namePart><namePart type="family">Mohr</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>CroMedica Global Inc., Victoria, Canada and University of Ottawa, Canada</affiliation><description>Correspondence: CroMedica Global Inc., 600‐730 View Street, Victoria BC, V8W 3Y7, Canada</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tilak</namePart><namePart type="family">Mendis</namePart><namePart type="termsOfAddress">MD, FRCP(C)</namePart><affiliation>Ottawa Civic Hospital and University of Ottawa, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kathleen</namePart><namePart type="family">Hildebrand</namePart><affiliation>CroMedica Global Inc., Victoria, Canada and University of Ottawa, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Peter Paul</namePart><namePart type="family">De Deyn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Middelheim Hospital, University of Antwerp, Antwerp, Belgium</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">shortCommunication</genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2000-11</dateIssued><dateCaptured encoding="w3cdtf">1999-09-28</dateCaptured><dateValid encoding="w3cdtf">2000-05-09</dateValid><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="tables">4</extent><extent unit="references">50</extent><extent unit="words">4166</extent></physicalDescription><abstract lang="en">PURPOSE: To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine‐induced psychosis. PATIENTS AND METHODS: Seventeen patients (median age, 72 yrs) participated in this 12‐week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued. EFFICACY RESULTS: Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (−3.1 decrease) after 1 week and a 66% improvement (−6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)‐severity and CGI‐improvement (p <0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). SAFETY RESULTS: Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs. CONCLUSION: Short‐term use of risperidone (mean dosage, 1.1 mg per day) improves the psychopathology of patients with PD who have dopamine‐induced psychosis without adversely affecting the symptoms of PD. Higher doses and long‐term use were not addressed in this study and may be precluded by extrapyramidal side effects.</abstract><subject lang="en"><genre>Keywords</genre><topic>Risperidone</topic><topic>Parkinson's disease</topic><topic>Psychosis</topic><topic>Extrapyramidal symptoms</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>1230</start><end>1237</end><total>8</total></extent></part></relatedItem><identifier type="istex">8B1FBAD976A77EB092B13F06364277175FC64B7A</identifier><identifier type="DOI">10.1002/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9</identifier><identifier type="ArticleID">MDS1026</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2000 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>John Wiley & Sons, Inc.</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000900 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000900 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:8B1FBAD976A77EB092B13F06364277175FC64B7A
|texte= Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial
}}
| This area was generated with Dilib version V0.6.23. |  |